The reading behind Desert Peptides
These are the sources linked on this site. Each helps answer a particular question; none answers them all.
MOTS-c inside stressed cells
MOTS-c inside stressed cells. Kim and colleagues (2018) followed MOTS-c into the nucleus during cell stress. The finding concerns gene activity inside cells, not a treatment benefit in people.
MOTS-c, exercise and mouse performance
MOTS-c, exercise and mouse performance. Reynolds and colleagues (2021) measured natural MOTS-c after human exercise and tested treatment in mice. The performance gains came from mice; the two parts answer different questions.
Retatrutide and weight
Retatrutide and weight. Jastreboff and colleagues (2023) studied adults with obesity, or overweight plus a related condition, without diabetes, for 48 weeks in a phase 2 trial. Weight loss, digestive side effects and heart-rate changes belong together.
Retatrutide and liver fat
Retatrutide and liver fat. Sanyal and colleagues (2024) studied a subset of the retatrutide weight trial using MRI scans. Participants had obesity or overweight, excess liver fat and no type 2 diabetes. The result concerns liver fat, not proven prevention of liver failure.
How retatrutide might affect fuel use
How retatrutide might affect fuel use. Katsi and colleagues (2025) reviewed the three hormone-receptor targets and early trials. This helps explain the idea behind retatrutide; the individual studies provide the outcome results.
Semaglutide and weight loss
Semaglutide and weight loss. Wilding and colleagues (2021) studied adults with obesity, or overweight plus a weight-related condition, without diabetes, for 68 weeks. Both groups had lifestyle support. The averages describe that setting, not an individual forecast.
Semaglutide and heart health
Semaglutide and heart health. Lincoff and colleagues (2023) studied adults aged 45 or older with cardiovascular disease, a BMI of at least 27 and no diabetes. BMI relates weight to height. The main result combined cardiovascular death, nonfatal heart attack and nonfatal stroke.
After semaglutide treatment stopped
After semaglutide treatment stopped. Wilding and colleagues (2022) followed a subset after study treatment and lifestyle support ended. Weight regain makes the longer view worth discussing; it doesn't decide anyone's treatment duration.
Wegovy prescribing information
Wegovy prescribing information. The semaglutide label gives approved uses, warnings and limits for the products it covers. The injection and tablets have differences. The full wording matters more than a brand-name shortcut.
Ozempic injection prescribing information
Ozempic injection prescribing information. This semaglutide label covers the injection's uses in type 2 diabetes and certain related risks. It isn't the label for Ozempic tablets. The exact product matters.
FDA on withdrawn nominations and safety
FDA on withdrawn nominations and safety. The page current as of April 22, 2026 lists MOTS-c among withdrawn nominations and retains safety concerns. It gives no individual withdrawal date. Withdrawal is not clearance or compounding permission.
FDA on compounded medicines
FDA on compounded medicines. FDA explains why compounded medicines aren't FDA-approved and what that means for safety, effectiveness and quality. A prescription is a separate decision from FDA review of a product.
HHS on care across state lines
HHS on care across state lines. HHS describes licensing and registration routes for clinicians. A patient's location matters. This is general background for an access question, rather than confirmation that a particular service is available to you.